Plasma P-tau217 blood tests match amyloid PET for early Alzheimer pathology, offering scalable, noninvasive detection and forecasting cognitive decline risk years ahead.
Anthony Sireci, MD
Advertisement
Articles by Anthony Sireci, MD
Discover how blood-based biomarker testing revolutionizes Alzheimer diagnosis, offering a less invasive, efficient alternative to traditional methods.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Disaster Psychiatry: Lessons From 9/11 and COVID-19
2
New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose
3
The Postmodern Worldview and Contemporary Psychiatry
4
New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
5